Inclusion Criteria : 
   1.  Confirmed by histopathological or cytological examination;
   2.  The criteria for resectability is met
   3.  Has at least one evaluable lesion according to the RECIST  1.1 standard and has not received local treatment
Exclusion Criteria : 
   1.  Patients who previously received anti - programmed death receptor -  1 ( PD -  1 ) antibody , anti - programmed death ligand -  1 ( PD - L 1 ) antibody , anti - programmed death ligand -  2 ( PD - L 2 ) antibody or anti - cytotoxic T lymphocyte - associated antigen -  4 ( CTLA -  4 ) antibodies , including those who have participated in a JS 001 clinical study;
   2.  Patients who previously received any TACE , radiofrequency ablation and other liver cancer treatments;
   3.  Patients with a history of gastroesophageal varices or active cardia ulcers associated with a high risk of bleeding;
   4.  Patients who have upper gastrointestinal hemorrhage within  1 year;
   5.  Patients known to have fibrous layer HCC , sarcomatoid HCC or mixed cholangiocarcinoma and HCC; Other protocol defined inclusion / exclusion criteria could apply